openPR Logo
Press release

mTOR Inhibitors Market: Research Key Players, Industry Overview and forecasts to 2020

mTOR Inhibitors Market: Research Key Players, Industry

mTOR Inhibitors Market: Overview

Mammalian target of rapamycin (mTOR) is a protein that regulates vital cell growth processes in a living organism. mTOR acts as a communication command centre in human body by receiving external signals from growth factors, hormones, proteins and transfer the signal to on’ or ’off’ mode for the cell to grow and divide. mTOR is considered as a member of the phosphatidylinositol 3-kinase (PI3K) cell survival pathway which plays an important role in the regulation of cell growth and proliferation. Akt proteins can be able to activate mTOR, which promotes cell growth and proliferation by stimulating protein synthesis. mTOR comprises two distinct multi protein complexes that includes mTOR complex 1 and mTOR complex 2. mTOR protein plays an important role in the regulation of various cancer cell such as breast cancer, colon cancer, ovarian cancer and cervical cancer.

Download PDF Brochure of Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2594

Many human cancer causes due to dysregulation of mTOR signaling and can confer higher susceptibility to mTOR inhibitors. Disregulation of mTOR signaling includes PI3K amplification/mutation, Phosphatase and Tensin Homolog (PTEN) loss of function, eIF4E protein over expression and over expression of protein kinase B. Thus, rising prevalence of various cancers (lung cancer, prostate cancer, breast cancer and cervical cancer) the global market for mTOR inhibitors is experiencing a significant growth worldwide. For instance, the World Health Organization (WHO) published in 2014, that worldwide 8.2 million people died of cancer in the year 2012. In 2013, American Cancer Society (ACS) published that, around 300,000 men and 276,000 women died due to cancer in 2012 in the U.S. California Journal of Clinical Cancer (CJCC) stated that, one in the every six U.S. men have received diagnosis test for prostate cancer at some point in their lives.

It has also stated that in 2010, 217,730 men were diagnosed with prostate cancer in the U.S. Moreover, National Centre for Biotechnology Information (NCBI) stated that, prevalence of prostate cancer is more in geriatric people (above 65 years of age). Thus, growing geriatric population also fuels the global market demand of mTOR inhibitors. However, high cost and technical complexity associated with the diagnosis procedure (detection) of mTOR would hinder the global market demand during the study period.

Request to View TOC of Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2594

North America and Europe was observed to be the largest mTOR inhibitors market due to major market players are based in these regions. Moreover, North America and Europe accounted for the highest number of diagnosis cases performed with respect to various cancer (lung cancer, prostate cancer, breast cancer and cervical cancer) every year. In addition, favorable initiatives taken by the federal government also accounted for the mTOR inhibitors market growth in North American and European regions. Similarly, Asia-Pacific is considered as an untapped market due to lack of proper healthcare facilities in some Asian countries.

Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget). Similarly, Asia-Pacific is considered as an emerging market due to growing market penetration in this region. Rest of the World (RoW) holds fourth position in the global mTOR inhibitors market due to poor economic and health condition in most of the African countries.

Various key players contributing the global market share of mTOR inhibitors market include LC Laboratories, UniProt, Biotool, Exelixis, Inc., Novartis AG, Enzymlogic, BioLegend, Inc., Enzo Biochem, Cell Signaling Technology, Inc., Fluofarma among others.

Request to View Discount –
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2594

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release mTOR Inhibitors Market: Research Key Players, Industry Overview and forecasts to 2020 here

News-ID: 1058538 • Views:

More Releases from Transparency Market Research

Acromegaly Treatment Market to Reach USD 3.1 Billion by 2035, Driven by Diagnostic Advancements, Oral Drug Innovations, and Rising Disease Awareness | TMR
Acromegaly Treatment Market to Reach USD 3.1 Billion by 2035, Driven by Diagnost …
The global Acromegaly Treatment Market is experiencing a significant transformation as improved early diagnosis, innovative therapeutic formulations, and regulatory support converge to expand patient access and drive substantial growth. According to the latest industry analysis, the global market, valued at US$ 1.5 billion in 2024, is projected to reach US$ 3.1 billion by 2035, progressing at a CAGR of 6.7% from 2025 to 2035. Gain a preview of important insights from
Forensic Genomics Market Projected to Surge to USD 2.4 Billion by 2035 as NGS, AI/ML Bioinformatics and Portable DNA Devices Transform Criminal Investigations | TMR
Forensic Genomics Market Projected to Surge to USD 2.4 Billion by 2035 as NGS, A …
The global Forensic Genomics Market is undergoing a period of accelerated transformation and expansion as next-generation sequencing (NGS), advanced PCR workflows, and AI/ML-driven bioinformatics redefine the capabilities of modern forensic investigations. According to the latest industry analysis, the market-valued at US$ 0.5 billion in 2024-is projected to reach approximately US$ 2.4 billion by 2035, expanding at a compound annual growth rate (CAGR) of 14.5% between 2025 and 2035. Access key findings
Planetary Roller Screw Market to Reach USD 1.1 Billion by 2035 as Demand for High-Load, High-Precision Actuation Systems Accelerates Worldwide | TMR
Planetary Roller Screw Market to Reach USD 1.1 Billion by 2035 as Demand for Hig …
The global Planetary Roller Screw Market is poised for substantial expansion over the next decade, driven by rising demand for high-load, high-precision performance in harsh industrial environments, rapid technological advancements, and the ongoing global shift toward electrified and automated systems. According to the latest industry intelligence, the market-valued at US$ 610.0 Mn in 2024-is projected to reach US$ 1,105.0 Mn by 2035, advancing at a compound annual growth rate (CAGR)
Chemical Absorbent Cotton Market Set to Reach USD 600.1 Million by 2035 Driven by Sustainability Initiatives, Regulatory Compliance, and Rising Industrial Demand
Chemical Absorbent Cotton Market Set to Reach USD 600.1 Million by 2035 Driven b …
The global Chemical Absorbent Cotton Market is entering a phase of sustained expansion, backed by rapid industrialization, strengthened environmental regulations, and growing adoption of biodegradable absorbent solutions across healthcare, chemical handling, automotive, and industrial safety applications. According to the latest industry analysis, the global market-valued at US$ 340.0 million in 2024-is projected to reach US$ 600.1 million by 2035, expanding at a CAGR of 5.4% from 2025 to 2035. Access key

All 5 Releases


More Releases for Inhibitors

Thymidine Phosphorylase Inhibitors Market - Breaking the Cycle: Angiogenesis Inh …
Newark, New Castle, USA: The "Thymidine Phosphorylase Inhibitors Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Thymidine Phosphorylase Inhibitors Market: https://www.growthplusreports.com/report/thymidine-phosphorylase-inhibitors-market/8826 This latest report researches the industry structure,
CGRP Inhibitors Market - Break Free from Migraine: CGRP Inhibitors Redefining Re …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global CGRP Inhibitors Market. CGRP Inhibitors Market: https://www.growthplusreports.com/report/cgrp-inhibitors-market/9155 The CGRP Inhibitors Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy.
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy 1.1 Overview 1.2 History- From Tragedy to Breakthrough Major Immune Checkpoints Proteins 2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development 2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development Mechanism of Action of Immune Checkpoint Inhibitors 3.1 Cytotoxic T lymphocyte Antigen-4
Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …
Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity. The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab